13F Holdings
中文EN

TLRY Tilray Brands, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1731348 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.9%
TTM net income YoY92.4%
TTM EPS YoY94.2%
Revenue 3-yr CAGR14.0%
Net income 3-yr CAGR—

Margins

Gross margin29.1%
Operating margin-9.3%
Net margin-17.1%
FCF margin—
EBITDA margin—

Returns

ROE-10.4%
ROA-7.4%
ROIC (approx.)-5.0%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.08x
Current ratio1.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.51x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31FY20242024-05-31FY20232023-05-31FY20222022-05-31
Income statement
Revenue$915.45M$821.31M$788.94M$627.12M$628.37M
Cost of revenue$655.01M$580.74M$565.59M$480.16M$511.56M
Gross profit$260.44M$240.57M$223.35M$146.96M$116.82M
R&D expense$361,000$284,000$635,000$682,000$1.52M
SG&A expense$203.63M$167.32M$167.36M$165.16M$162.80M
Operating income-$63.03M-$2.28B-$174.75M-$1.37B-$610.40M
Interest expense$29.91M$41.33M$49.26M$46.61M$39.68M
Pretax income-$88.06M-$2.30B-$249.02M-$1.45B-$440.67M
Income tax$17.10M-$121.02M-$26.62M-$7.18M-$6.54M
Net income-$121.40M-$2.19B-$244.98M-$1.45B-$476.80M
EBITDA————-$455.81M
EPS (basic)-1.09-24.56-3.30-2.35-0.99
EPS (diluted)-1.09-24.56-3.30-2.35-0.99
Weighted avg. shares (diluted)111.83M89.03M74.26M617.98M481.22M
Balance sheet
Cash & equivalents$225.98M$221.67M$228.34M$206.63M$415.91M
Short-term investments$5.29M$34.70M$32.18M$241.90M$0
Receivables$189.17M$121.49M$101.69M$86.23M$95.28M
Inventory$301.19M$270.88M$252.09M$200.55M$245.53M
Current assets$792.13M$688.63M$677.71M$773.03M$803.50M
PP&E, net$680.23M$568.43M$558.25M$429.67M$587.50M
Goodwill$752.35M$752.35M$2.01B$2.01B$2.64B
Intangibles$42.78M$21.42M$915.47M$973.78M$1.28B
Total assets$2.33B$2.07B$4.22B$4.31B$5.45B
Current liabilities$358.38M$280.30M$299.17M$432.98M$280.34M
Short-term debt$8.78M$7.18M$18.03M$23.38M$18.12M
Long-term debt$120.42M———$117.88M
Total debt$129.20M———$136.00M
Total liabilities$733.14M$584.75M$778.49M$977.32M$1.01B
Shareholders' equity$1.61B$1.51B$3.44B$3.32B$4.40B
Net debt-$96.78M———-$279.91M
Shares outstanding131.68M106.07M831.93M656.66M532.67M
Cash flow statement
Operating cash flow-$69.14M-$94.60M-$30.91M$7.91M-$177.26M
Capital expenditure—$32.92M$29.25M$20.80M$34.06M
Free cash flow—-$127.52M-$60.15M-$12.89M-$211.33M
Investing cash flow-$55.80M-$46.72M$128.35M-$285.11M-$21.53M
Financing cash flow$130.99M$133.51M-$75.19M$70.16M$128.20M
Depreciation & amortization————$154.59M
Stock-based compensation$45.94M$24.29M$31.77M$39.59M$35.99M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.